Publications by authors named "Martin Oft"

Claim this Profile
A
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy.
Ievgen Koliesnik, Michael Totagrande, Bhargavi Jayaraman, Ryan Burgess, Kim Quyen Tran, Martin Oft

Cell Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists.
Raphael Trenker, Deepti Rokkam, Andrew Morin, Priyanka Balasubrahmanyam, Verenice Paredes, Martin Oft

Antibodies (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-2 based cancer immunotherapies: an evolving paradigm.
Sushama Rokade, Anita Mehta Damani, Martin Oft, Jan Emmerich

Front Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma.
Paul-Joseph Aspuria, Sandro Vivona, Michele Bauer, Marie Semana, Navneet Ratti, Martin Oft

Sci Transl Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, Manish R Patel, Jeffrey R Infante, Martin Oft

Invest New Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Aung Naing, Deborah J Wong, Jeffrey R Infante, W Michael Korn, Raid Aljumaily, Martin Oft

Lancet Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience.
Martin Oft

Semin Immunol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 10-Mediated Response and Correlated Anemia in a Patient with Advanced Non-Small Cell Lung Carcinoma.
Khalil Choucair, Jesse D Kelso, Joseph R Duff, Christine S Cassidy, Mary T Albrethsen, Martin Oft

Case Rep Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.
Karen Autio, Martin Oft

Curr Oncol Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Aung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, Ivan H Chan, Cong Shen, Martin Oft

Cancer Cell· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.
Ivan H Chan, Dennis Van Hoof, Marina Abramova, Melissa Bilardello, Elliot Mar, Martin Oft

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, Patrick A Ott, Manish R Patel, Martin Oft

J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells.
Ivan Ho Chan, Victoria Wu, Melissa Bilardello, Elliot Mar, Martin Oft

J Interferon Cytokine Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-10: master switch from tumor-promoting inflammation to antitumor immunity.
Martin Oft

Cancer Immunol Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No immunosurveillance in human IL-10R deficiency.
Martin Oft

Blood· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity.
John B Mumm, Martin Oft

Bioessays· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer.
Nichole R Blatner, Mary F Mulcahy, Kristen L Dennis, Denise Scholtens, David J Bentrem, Martin Oft

Sci Transl Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Killing from within.
John B Mumm, Jan Emmerich, Martin Oft

Oncoimmunology· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells.
Jan Emmerich, John B Mumm, Martin Oft

Oncoimmunology· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs.
Jan Emmerich, John B Mumm, Ivan H Chan, Drake LaFace, Hoa Truong, Martin Oft

Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-10 elicits IFNγ-dependent tumor immune surveillance.
John B Mumm, Jan Emmerich, Xueqing Zhang, Ivan Chan, Lingling Wu, Martin Oft

Cancer Cell· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subversion and coercion: the art of redirecting tumor immune surveillance.
John B Mumm, Martin Oft

Curr Top Microbiol Immunol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
David Parry, Timothy Guzi, Frances Shanahan, Nicole Davis, Deepa Prabhavalkar, Martin Oft

Mol Cancer Ther· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization.
Jeremy P McAleer, Bei Liu, Zihai Li, Soo-Mun Ngoi, Jie Dai, Martin Oft

J Leukoc Biol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.
Michele W L Teng, Daniel M Andrews, Nicole McLaughlin, Bianca von Scheidt, Shin Foong Ngiow, Martin Oft

Proc Natl Acad Sci U S A· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis